Oncotarget

Research Papers:

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC

Joseph D. Coppock, Paola D. Vermeer, Daniel W. Vermeer, Kimberly M. Lee, W. Keith Miskimins, William C. Spanos and John H. Lee _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:24228-24241. https://doi.org/10.18632/oncotarget.8286

Metrics: PDF 1134 views  |   HTML 1372 views  |   ?  


Abstract

Joseph D. Coppock1, Paola D. Vermeer1, Daniel W. Vermeer1, Kimberly M. Lee1, W. Keith Miskimins1, William C. Spanos1,2, John H. Lee1,2

1Cancer Biology Research Center, Sanford Research/USD, Sioux Falls, SD 57104, USA

2Department of Otolaryngology/Head and Neck Surgery, Sanford Health, Sioux Falls, SD 57105, USA

Correspondence to:

John H. Lee, e-mail: john.lee@sanfordhealth.org

Keywords: head and neck oral cancer, human papillomavirus, metastasis, rapamycin, mTOR

Received: October 19, 2015     Accepted: March 06, 2016     Published: March 23, 2016

ABSTRACT

Effective treatments for recurrent/metastatic human papillomavirus-positive (HPV+) head and neck squamous cell cancer (HNSCC) are limited. To aid treatment development, we characterized a novel murine model of recurrent/metastatic HPV+ HNSCC. Further analysis of the parental tumor cell line and its four recurrent/metastatic derivatives led to preclinical testing of an effective treatment option for this otherwise fatal disease. Reverse phase protein arrays identified key signaling cascades in the parental and recurrent/metastatic cell lines. While protein expression profiles differed among the recurrent/metastatic cell lines, activated proteins associated with the mTOR signaling cascade were a commonality. Based on these data, mTOR inhibition was evaluated as an adjuvant treatment for recurrent/metastatic disease. mTOR activity and treatment response were assessed in vitro by western blot, Seahorse, proliferation, clonogenic, and migration assays. Standard-of-care cisplatin/radiation therapy (CRT) versus CRT/rapamycin were compared in vivo. Low-dose rapamycin inhibited mTOR signaling, decreasing proliferation (43%) and migration (62%) while it enhanced CRT-induced cytotoxicity (3.3 fold) in clonogenic assays. Furthermore, rapamycin re-sensitized CRT-resistant, metastatic tumors to treatment in vivo, improving long-term cures (0–30% improved to 78–100%, depending on the recurrent/metastatic cell line) and limiting lymph node metastasis (32%) and lung metastatic burden (30 fold). Studies using immune compromised mice suggested rapamycin’s effect on metastasis is independent of the adaptive immune response. These data suggest a role of mTOR activation in HPV+ HNSCC recurrent/metastatic disease and that adjuvant mTOR inhibition may enhance treatment of resistant, metastatic cell populations at the primary site and limit distant metastasis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8286